ADTRALZA 150 mg Injection Solution for

What is ADTRALZA 150 mg

ADTRALZA is a prescription biologic medication containing the active substance tralokinumab, a fully human monoclonal antibody. It is designed for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults who are candidates for systemic therapy. scottishmedicines.org.uk +2 ec.europa.eu +2 en.wikipedia.org +2 Key Features: Active Ingredient: Tralokinumab Formulation: 150 mg/mL solution in pre-filled syringes Administration: Subcutaneous injection Packaging: Available in packs of 4 (2 packs of 2) pre-filled syringes Indication: Treatment of moderate-to-severe atopic dermatitis in adults scottishmedicines.org.uk +1 en.wikipedia.org +1 Tralokinumab works by targeting and neutralizing interleukin-13 (IL-13), a cytokine involved in the inflammatory processes of atopic dermatitis. By inhibiting IL-13, ADTRALZA helps reduce skin inflammation, itching, and other symptoms associated with eczema .

How to use ADTRALZA 150 mg

ADTRALZA is administered via subcutaneous injection. Patients may self-inject after proper training by a healthcare professional. Administration Guidelines: Initial Dose: 600 mg, given as four 150 mg injections at different sites on the same day. Maintenance Dose: 300 mg, administered as two 150 mg injections every other week. Injection Sites: Thighs, abdomen (avoiding a 5 cm area around the navel), or upper arms (if administered by someone else). Preparation: Allow the syringe to reach room temperature (approximately 30 minutes) before injection. Do not shake the syringe. Inspect the solution for clarity; it should be clear to opalescent and colorless to pale yellow. Missed Dose: If a dose is missed, administer it as soon as possible and resume the regular dosing schedule . se.dermaworld.eu Always follow the specific instructions provided by your healthcare provider regarding injection technique and site rotation. rexall.ca

Mode of Action ADTRALZA 150 mg

ADTRALZA contains tralokinumab, which is a fully human IgG4 monoclonal antibody that specifically binds to interleukin-13 (IL-13). Mechanism Details: Target: IL-13, a cytokine involved in the inflammatory response in atopic dermatitis. Action: By binding to IL-13, tralokinumab prevents its interaction with IL-13 receptors, thereby inhibiting the downstream inflammatory signaling pathways. Result: Reduction in skin inflammation, improvement in skin barrier function, and alleviation of symptoms such as itching and redness . This targeted approach helps in managing the chronic inflammation characteristic of atopic dermatitis.

ADTRALZA 150 mg Interactions ADTRALZA 150 mg

While tralokinumab is not metabolized by liver enzymes and has a low potential for drug-drug interactions, certain considerations should be noted: ema.europa.eu Drug Interactions: Live Vaccines: Avoid concurrent administration with live or live-attenuated vaccines due to potential risk of infection. Complete necessary vaccinations before initiating therapy . Non-Live Vaccines: Can be administered safely; studies have shown no adverse interactions . Immunosuppressants: Caution is advised when used concomitantly with other immunosuppressive agents; monitor for increased risk of infections. reference.medscape.com medicines.org.uk Always inform your healthcare provider about all medications and supplements you are taking to assess potential interactions.

Dosage of ADTRALZA 150 mg

The dosing regimen for ADTRALZA is as follows: Recommended Dosage: Initial Dose: 600 mg, administered as four 150 mg subcutaneous injections on the same day. Maintenance Dose: 300 mg, given as two 150 mg injections every other week. Alternative Maintenance: For patients achieving clear or almost clear skin after 16 weeks, a maintenance dose of 300 mg every four weeks may be considered . scottishmedicines.org.uk Dosage adjustments should be made based on clinical response and under the guidance of a healthcare professional.

Possible side effects of ADTRALZA 150 mg

Like all medications, ADTRALZA may cause side effects. Not all patients will experience these, and many side effects are mild and manageable. Common Side Effects: Upper respiratory tract infections (e.g., sore throat, nasal congestion) Injection site reactions (redness, pain, swelling) Conjunctivitis (eye redness and discomfort) Headache Elevated eosinophil levels in blood tests ema.europa.eu en.wikipedia.org Less Common Side Effects: Fatigue Fever Nausea Hypersensitivity reactions (e.g., rash, hives) medicines.org.uk +28 ema.europa.eu +28 rexall.ca +28 If you experience any severe or persistent side effects, contact your healthcare provider promptly.

ADTRALZA 150 mg Contraindications ADTRALZA 150 mg

ADTRALZA should not be used in certain situations: Contraindications: Hypersensitivity: Known allergy to tralokinumab or any of the excipients in the formulation. Active Infections: Should not be initiated in patients with active or chronic infections until the infection is resolved. Pregnancy and Lactation: Use only if the potential benefit justifies the potential risk to the fetus or infant. Limited data are available . Pediatric Use: Safety and efficacy have not been established in children under 12 years of age . medbroadcast.com Discuss your medical history thoroughly with your healthcare provider before starting ADTRALZA.

Storage of ADTRALZA 150 mg

Proper storage of ADTRALZA is essential to maintain its efficacy: Storage Instructions: Refrigeration: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Room Temperature: If necessary, the pre-filled syringes may be kept at room temperature (up to 25°C or 77°F) for a maximum of 14 days. Do not return to the refrigerator once stored at room temperature . Protection from Light: Keep the syringes in the original carton to protect from light. Do Not Freeze: Avoid freezing the medication. Disposal: Dispose of any unused or expired medication according to local regulations. eczema.org +1 myleopharma.com +1 myleopharma.com +1 reference.medscape.com +1 Always check the expiration date and consult your pharmacist or healthcare provider if you have any questions about storage.